On January 24, 2023 MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, reported that its Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Steven B. Binder, will participate in the Lytham Partners Investor Select Conference taking place virtually on Tuesday, January 31, 2023 (Press release, Mannkind, JAN 24, 2023, View Source [SID1234626495]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s webcast presentation will be available for viewing at 9:00am ET on Tuesday, January 31, 2023, on the Company’s website at Events & Presentations or View Source The webcast will also be archived and available for replay.

Management will be participating in virtual one-on-one meetings. To arrange a meeting with management, please contact Lytham Partners at 1×[email protected].